1. 基本信息
2. 近三年获得的项目基金
PI = Principal Investigator
PC = Project Coordinator
Health and Medical Research Fund 2018 (PI)
Project Title: Functional characterization of fucosyltransferase 1 (FUT1) in promoting cancer stemness properties in hepatocellular carcinoma
Project No. 07183206; Funded $1,499,557 HK; Funding Period: 24 Feb 2020 – 23 Feb 2023.
Research Grants Council – Collaborative Research Fund 2018/19 (PC)
Project Title: Exploiting stemness as a cancer cell vulnerability using hepatocellular carcinoma (HCC) as a model system
Project No. C7026-18G; Funded $6,990,790 HK; Funding Period: 1 Apr 2019 – 31 Mar 2022.
RGC GRF 2020/21 (PI)
Project Title: AGPAT4: a novel metabolic driver of stemness in hepatocellular carcinoma?
Project No. 17112520; Funded $996,285 HK; Funding Period: 1 Jan 2021 – 31 Dec 2023
RGC Research Impact Fund (RIF) 2020/21 (PC)
Project Title: Development and applications of a driver-dependent tumor organoid biobank for translational liver cancer research
Project No. R7022-20; Funded $4,100,000 HK by RGC (plus 30% match by institute); Total Funded $5,857,143; Funding Period: 1 Jun 2021 – 31 May 2025
NSFC – General Program 2020 (PI)
Project Title: Biological and clinical relevance of serpin family A member 12 (SERPINA12) in maintenance of cancer stemness properties in hepatocellular carcinoma
Project No. 82073279; Funded $570,000 RMB; Funding Period: 1 Jan 2021 – 31 Dec 2024
ITF – ITSP Seed Project 2020 (PI)
Project Title: Development and pre-clinical evaluation of a humanized ANXA3 neutralizing monoclonal antibody for hepatocellular carcinoma treatment
Project No. ITS/262/20; Funded $1,250,000 HK; Funding Period: 1 Jun 2021 – 31 Dec 2022
RGC GRF 2021/22 (PI)
Project Title: Role of the lipid metabolic regulator DGKH in driving stemness in hepatocellular carcinoma
Project No. 17112021; Funded $1,125,732 HK; Funding Period: 1 Jan 2022 – 31 Dec 2024
RGC Research Fellow Scheme 2021/22 (PI)
Project Title: An immune perspective on exploiting stemness as a cancer cell vulnerability for the treatment of liver cancer
Funded $5,115,380 HK; Funding Period: 1 Jan 2022 – 31 Dec 2026
3. 近三年发表科研论文
Total number of citations >5620; h-index 37 (Source: Scopus; Author ID: 16444895800)
^ denotes corresponding author and * denotes co-first authorship
2020 Journal Impact Factor (IF) and Ranking; Citations as of Jul 26 2021 (Source: Scopus)
Top 1% of most cited scholars in ‘clinical medicine’ and ‘all fields’ of ISI Essential Science Indicators (2010-2018).
As first or corresponding author
1. Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo CM, Man K, Ding J, Lee TK, Ma S^. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol 2018; 69(4):826-39.
IF 25.083; Rank 2/92 (Gastroenterology & Hepatology); Cites 41
2. Chan LH*, Zhou L*, Ng KY*, Wong TL*, Lee TK, Sharma R, Loong JH, Ching YP, Yuan YF, Xie D, Lo CM, Man K, Artegiani B, Clevers H, Yan HH, Leung SY, Richard S, Guan XY, Huen MS, Ma S^. Protein arginine methyltransferase PRMT6 regulates RAS/RAF binding and MEK/ERK-mediated cancer stemness activities in hepatocellular carcinoma through CRAF methylation. Cell Rep 2018; 25:690-701.
IF 9.423; Rank 33/195 (Cell Biology); Cites 33
3. Wong TL, Ng KY, Tan KV, Chan LH, Zhou L, Che N, Hoo RL, Lee TK, Richard S, Lo CM, Man K, Khong PL, Ma S^. CRAF methylation by PRMT6 regulates aerobic glycolysis driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. Hepatology 2020; 71:1279-96.
IF 17.425; Rank 6/92 (Gastroenterology & Hepatology); Cites 17
4. Leung CO*, Tong M*, Chung KP, Zhou L, Che N, Tang KH, Ding J, Lau EY, Ng IO, Ma S^, Lee TK^. Overriding the adaptive resistance to sorafenib through combination therapy with SHP2 blockade in hepatocellular carcinoma. Hepatology 2020; 72:155-68.
IF 17.425; Rank 6/92 (Gastroenterology & Hepatology); Cites 12
5. Luk ST, Ng KY, Zhou L, Tong M, Wong TL, Yu HJ, Lo CM, Man K, Guan XY, Lee TK, Ma S^. Deficiency in embryonic stem cell marker REX1 activates MKK6-dependent p38 MAPK signaling to drive hepatocarcinogenesis. Hepatology 2020; 72:183-97.
IF 17.425; Rank 6/92 (Gastroenterology & Hepatology); Cites 7
6. Che N*, Ng KY*, Wong TL, Tong M, Kau PW, Chan LH, Sharma R, Lee TK, Huen MS, Yun JP, Ma S^. PRMT6 deficiency induces autophagy in hostile microenvironment of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability. Cancer Lett 2021; 501:247-62.
IF 8.679; Rank 34/242 (Oncology)
7. Ng KY, Shea QT, Wong TL, Luk ST, Tong M, Lo CM, Man K, Yun JP, Guan XY, Lee TK, Zheng YP, Ma S^. Chemotherapy enriched THBS2-deficient cancer stem cells drive hepatocarcinogenesis through matrix softness induced histone H3 modifications. Adv Sci 2021; 8:2002483.
IF 16.806; Rank 9/107 (Nanoscience & Nanotechnology), 18/335 (Materials Science, Multidisciplinary)
8. Loong JH, Wong TL, Tong M, Sharma R, Zhou L, Ng KY, Yu HJ, Li CH, Man K, Lo CM, Guan XY, Lee TK, Yun JP, Ma S^. Stabilization of CD147 via α1,2-fucosylation by FUT1 drives cancer stemness in a glucose restricted hepatocellular carcinoma microenvironment. J Clin Invest 2021; 131:143377.
IF 14.808; Rank 3/140 (Medicine, Research & Experimental); Cites 1
9. Tong M^, Wong TL, Zhou HZ, Zheng YY, Li CH, Zhou L, Wong KY, Huen MS, Xie YN, Che N, Man K, Yun JP, Guan XY, Lee TK, Cai Z^, Ma S^. Loss of tyrosine catabolism drives tumorigenesis in early hepatocellular carcinoma by reprogramming glutamine metabolism. Cell Rep 2021; accepted.
IF 9.423; Rank 33/195 (Cell Biology)
10. Loh JJ, Li TW, Zhou L, Wong TL, Liu X, Ma VW, Lo CM, Man K, Lee TK, Ning W, Tong M^, Ma S^. FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness. Cancer Res 2021; accepted.
IF 12.701; Rank 17/242 (Oncology)
11. Zhou L*, Ho KY*, Wong TL*, Zhang Z, Loong JH, Che N, Yu HJ, Tan KV, Tong M, Ngan ES, HO JW^, Ma S^. Lineage tracing and single-cell analysis reveal Prom1+ transit-amplifying tumor progenitors and its dynamic cellular transition during liver cancer progression. Gut 2021; accepted.
IF 23.059; Rank 3/92 (Gastroenterology & Hepatology)
12. Zheng Y*, Zhao H*, Tong M, Zhu L, Ma S^, Cai Z^. Characterization and determination of 13C-labeled non-essential amino acids in 13C5-glutamine isotope tracer experiment with a mass spectrometry strategy combining parallel reaction monitoring and multiple reaction monitoring. Anal Chem 2021; accepted.
IF 6.986; Rank 8/83 (Chemistry, Analytical)
13. Xu F*, Tong M*, Tong CS, Chan BK, Chu HY, Wong TL, Fong JH, Cheung MS, Mak KH, Pardeshi L, Huang Y, Wong KH, Choi CG, Ma S^, Wong AS^. A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment. Cancer Res 2021; accepted.
IF 12.701; Rank 17/242 (Oncology)
14. Lee TK, Guan XY, Ma S^. Cancer stem cells in hepatocellular carcinoma: from origin to clinical implications. Nat Rev Gastroenterol Hepatol 2021; Sep 9. doi: 10.1038/s41575-021-00508-3.
IF 46.802; Rank 1/92 (Gastroenterology & Hepatology)
15. Loh JJ, Ma S^. The role of cancer-associated fibroblasts as a dynamic player in mediating cancer stemness in the tumor microenvironment. Front Cell Dev Biol 2021; accepted.
IF 6.684; Rank 52/195 (Cell Biology), 6/41 (Developmental Biology)
As co-author
1. Cheng BY, Lau EY, Leung DH, Ho NP, Cheng LK, Lin CH, Lo RC, Ma S, Ng IO, Lee TK. IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res 2018; 78(9):2332-42.
IF 12.701; Rank 17/242 (Oncology); Cites 28
2. Sin ST, Li Y, Liu M, Yuan YF, Ma S, Guan XY. Down-regulation of TROP-2 predicts poor prognosis of hepatocellular carcinoma patients. Hepatol Commun 2018; 2:1408-14.
IF 5.073; Rank 32/92 (Gastroenterology & Hepatology)
3. Yan HH, Siu HC, Law S, Ho SL, Yue SS, Tsui WY, Chan D, Chan AS, Ma S, Lam KO, Bartfeld S, Man AH, Lee BC, Chan AS, Wong JW, Cheng PS, Chan AK, Zhang J, Shi J, Fan X, Kwong DL, Mak TW, Yuen ST, Clevers H, Leung SY. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell 2018; 23:882-97.
IF 24.633; Rank 1/29 (Cell & Tissue Engineering) and 9/195 (Cell Biology); Cites 131
4. Hu H, Gehart H, Artegiani B, Lopez-Iglesias C, Dekkers F, Basak O, van Es J, Chuva de Sousa Lopes SM, Begthel H, Korving J, van den Born M, Zou C, Quirk C, Chiriboga L, Rice CM, Ma S, Rios A, Peters PJ, de Jong YP, Clevers H. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell 2018; 175:1591-606.
IF 41.582; Rank 2/298 (Biochemistry & Molecular Biology) and 3/195 (Cell Biology); Cites 156
5. Sin ST, Li Y, Liu M, Ma S, Guan XY. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol Oncol 2019; 152:185-93.
IF 5.482; Rank 8/83 (Obstetrics & Gynecology), 79/242 (Oncology); Cites 5
6. Han L, Cui D, Li B, Xu WW, Lam AK, Chan KT, Zhu Y, Lee NP, Law S, Guan XY, Qin YR, Chan KW, Ma S, Tsao SW, Cheung AL. Role of miR-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells via targeting Id-1. Cancer Science 2019; 110:3677-88.
IF 6.716; Rank 50/242 (Oncology); Cites 12
7. Leung HW*, Lau EY*, Leung CO, Lei MM, Mok EH, Ma V, Cho WC, Ng IO, Yun JP, Cai SH, Yu HJ, Ma S, Lee TK. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma. Cancer Lett 2020; 476:48-56.
IF 8.679; Rank 34/242 (Oncology); Cites 11
8. Liu M*, Yan Q*, Sun Y*, Nam Y, Hu L, Loong JH, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang L, Fang S, Yang X, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang J, Guan XY. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Proc Natl Acad Sci USA 2020; 117:6103-13.
IF 10.7; Rank 3/48 (Multidisciplinary Sciences); Cites 6
9. Huang YH*, Zhang CZ*, Huang QS*, Yeong J, Wang F, Yang X, He YF, Zhang XL, Zhang H, Chen SL, Zheng YL, Deng R, Lin CS, Yang MM, Li Y, Jiang C, Lee TK, Ma S, Zeng MS, Yun JP. Clinicopathologic features, tumor immune microenvironment and genomic landscape of EBV-associated intrahepatic cholangiocarcinoma. J Hepatol 2021; 74:838-49.
IF 25.083; Rank 2/92 (Gastroenterology & Hepatology); Cites 1
10. Yan Q*, Zhang Y*, Fang X*, Liu B, Wong TL, Gong L, Liu S, Yu D, Liu M, Jiang L, Wang X, Wei T, Jia Y, Li L, Sun L, Tang Y, Yuan YF, Li Y, Ma S, Guan XY. PGC7 promotes tumor oncogenic dedifferentiation through remodeling DNA methylation pattern for key developmental transcription factors. Cell Death Diff 2021; 28:1955-70.
IF 15.828; Rank 12/298 (Biochemistry & Molecular Biology), 15/195 (Cell Biology); Cites 1
11. Kong FE*, Li GM*, Tang YQ*, Xi SY, Loong JH, Li MM, Li HL, Cheng W, Zhu WJ, Mo JQ, Gong YF, Tang H, Zhao Y, Zhang Y, Ma S, Guan XY, Ma NF, Xie MB, Liu M. Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Trans Med 2021;13:eabb622.
IF 17.956; Rank 13/195 (Cell Biology), 2/140 (Medicine, Research & Experimental); Cites 2
12. Ho NP*, Leung CO*, Wong TL, Lau EY, Lei MM, Mok EH, Leung HW, Tong M, Ng IO, Jun JP, Ma S, Lee TK. The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression. Cell Death Dis 2021; 12:148.
IF 8.469; Rank 37/195 (Cell Biology); Cites 1
13. Yang XD*, Kong FE*, Qi L*, Lin JX*, Yan Q, Loong JH, Xi SY, Zhao Y, Zhang Y, Yuan YF, Ma NF, Ma S, Guan XY, Liu M. PARP inhibitor olaparib overcomes sorafenib resistance through remodeling the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer 2021; 20:20.
IF 27.401; Rank 10/242 (Oncology), 3/298 (Biochemistry & Molecular Biology); Cites 4
14. Leung HW, Leung CO, Lau EY, Chung KP, Mok EH, Lei MM, Leung RW, Tong M, Keng VW, Ma C, Zhao Q, Ng IO, Ma S, Lee TK. EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res 2021; 81:3229-40.
IF 12.701; Rank 17/242 (Oncology)
4. 近三年获得的人才称号
1. University of British Columbia Alumni Builder Award, Canada (2017/18)
The Alumni Builder Award recognizes alumni who have significantly contributed to the University and enriched the lives of others, and in doing so, have supported alumni UBC’s mission of realizing the promise of a global community with shared ambition of a better world and an exceptional UBC. The award recognizes UBC alumni who have made significant contributions to the university; demonstrated leadership and in doing so, made a lasting impact on Canada and UBC through their contribution. A total of 80 awards was made in 2017/18.
2. Ton Duc Thang University Scientific Prize – Rising Star Award, Vietnam (2018)
Established with the avowed purposes of honoring Vietnamese and international scientists who have excellent research and contribute positively to the society. Only one Rising Star Award was awarded.
3. Research Grants Council (RGC) Research Fellow (2021)
The RGC Research Fellow Scheme (RFS) aims to provide sustained support and relief from teaching and administrative duties to exceptionally outstanding researchers at Associate Professor rank at UGC-funded universities in HK, with a view to facilitating their full dedication to research and development and helping universities attract and retain research talent. Ten places encompassing all academic disciplines awarded in each round of this yearly exercise. Each awardee will receive a fellowship grant at ~$5.2 million HK over a period of 60 months.
5. 近三年获批的专利
6. 其他材料
Current Positions:
- Associate Professor, School of Biomedical Sciences, HKUMed (2018-Present)
- Associate Director, Knowledge Exchange and Global, School of Biomedical Sciences, HKUMed (2020-Present)
- Academic Lead, Imaging and Flow Cytometry Core, Centre for PanorOmic Sciences, HKUMed (2021-Present)
- Associate Director, Knowledge Exchange Office, HKU (2021-2022)
- Principal Investigator, State Key Laboratory of Liver Research (2011-Present)
- Honorary Research Fellow, Department of Clinical Oncology, University of Hong Kong – Shenzhen Hospital (2020-22)
- Founding Member and Chair of Outreach Committee, The Hong Kong Young Academy of Sciences (2018-Present)
- Member, Future Forum Young Scientist Innovation Alliance (2018-Present)
- Board Member, Hong Kong Science and Technology Parks Corporation (2020-Present)
- Board Member, International Society of Differentiation (2020-2026)
- Associate Editor, Experimental Cell Research (2020-2022)
- Editorial Board, Carcinogenesis (2019-Present)
- Editorial Board, Differentiation (2021-Present)
- Editorial Board, Hepatology (2022 onwards)
